Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of ONO-1101 in Patients Scheduled for Coronary Angiography

This study has been completed.
Information provided by (Responsible Party):
Ono Pharmaceutical Co. Ltd Identifier:
First received: November 16, 2007
Last updated: June 12, 2012
Last verified: June 2012
The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for coronary angiography, in a double-blind, randomized, placebo-controlled, parallel group, multi-center study.

Condition Intervention Phase
Coronary Artery Disease
Drug: ONO-1101
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Diagnostic
Official Title: Study of ONO-1101 in Patients Scheduled for Coronary Angiography, a Double-Blind, Randomized,Placebo-Controlled, Parallel Group, Multi-Center Study

Further study details as provided by Ono Pharmaceutical Co. Ltd:

Primary Outcome Measures:
  • CT image quality [ Time Frame: one day ]

Secondary Outcome Measures:
  • Heart rate [ Time Frame: For less than one month ]
  • CT diagnostic accuracy [ Time Frame: For less than one month ]

Enrollment: 183
Study Start Date: November 2007
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: P Drug: ONO-1101
placebo for 1 minute IV
Experimental: E2 Drug: ONO-1101
0.125 mg/kg for 1 minute IV
Experimental: E1 Drug: ONO-1101
0.06 mg/kg for 1 minute IV


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 20 years of age or older
  • Heart rate less than 90 beats/min and more than 70 beats/min at entering the CT room

Exclusion Criteria:

  • Previous allergic reactions to contrast agent
  • Renal failure
  • Asthma
  • Concomitant beta-receptor blocking agent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00560209

Kinki Region
Kinki, Japan
Sponsors and Collaborators
Ono Pharmaceutical Co. Ltd
Study Director: Shinichi Kikawa Ono Pharmaceutial Co., Ltd
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ono Pharmaceutical Co. Ltd Identifier: NCT00560209     History of Changes
Other Study ID Numbers: ONO-1101-26
Study First Received: November 16, 2007
Last Updated: June 12, 2012

Keywords provided by Ono Pharmaceutical Co. Ltd:
Coronary Artery Disease
Multi-slice CT

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents processed this record on May 25, 2017